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Unambiguous synthesis of all six possible 112,5,7-tri~ubstitu~ed(mono?enzyl, dimethyl)-4,6-dioxo-
4,5,6,7-tetrahydropyrazolo[3,4-d]pyrimidineshas been described. HIgh resolution (400 MHz) proton NMR
data of these compounds (10, 13, 19, 25a, 25b and 25c) have been discus~edand some unusu~l features
observed for phenyl protons have been rationalized due to hindered rotation when two substituents are
simultaneously present at 1- and 7-positions. \
Recently we have reported a convenient synthesis
of phidolopin 1 a marine natural product', related
to 7-benzyltheophylline 2 and its analogs
alongwith their biological activities". Caffeine 3
and theophylline 4, a drug for asthma are other
famous xanthines. Due to our continued interest.
in pyrazolo[3,4-d]pyrimidines3-6 we became
interested in the synthesis of pyrazolo[3,4-d]pyri-
midine analogs of phidolopin for the evaluation of
their biological activities. In connection with this
project we needed 'n NMR data of authentic 1/2-
benzyl-5, 7-dimethyl-4, 6-dioxo-4,5,6,7-tetrahydro-
pyrazolo[3,4-d] pyrimidines 10 and 25a. Literature
survey revealed that compound 10 has been
prepared earlier from I-benzyl-5-methyl-4,6-dioxo-
4,5,6,7-tetrahydropyrazolo[3,4-d]pyrimidine 9a in
about 30% yield without mention of isomeric 1-
benzyl-4-oxo-6-methoxy-5-methyl-4, 5-dihydropyra-
zoI0[3,4-d]pyrimidine 11 (R=Bzl) as a co-produce.
Furthermore as 1H NMR data of 10 was also not
reported we decided to make this compound from
the same starting material 9a. Synthesis 'of 9a was
achieved from compound 5a8 through inter-
mediates 6a and 8a (Scheme I). The reaction of Sa
with methyl iodide in dry DMF in presence of
anhyd. K2C03 gave a mixture of 6a and 7a.
Oxidation of the major product 6a with KMn04
gave new sulfone 8a which on treatment with
aqueous alkali gave known compound 9a in good
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1: R = CHrO-OH
2:R=CH~
3: R = CH3
4: R=H
yield. The methylation of 9a gave a mixture of two
isomeric products 10 and 11. The major product 10
(R=Bzl) had higher melting point (141°C) as
compared to the literature? melting point (133-
34°C). The major compound showing two N-Me.
signals in its 'it NMR spectrum at 8 3.38 and 3.57
was assigned structure 10. The minor compound
showing one N-Me singlet at 8 3.43 and another
singlet at 8 4.09 due to OMe in its 'n NMR was
assigned structure 11. Thus it is likely that lower
literature melting point of 10 was due to its
contamination by minute amount of 11.
Interestingly in the 'nNMR (400 MHz) of 11, fiye
phenyl protons were present as a rather broad
singlet centered at 8 7.3 while in the IH NMR of
10, corresponding protons were nicely split into
two sets of multiplets. The IH NMR of 10 showed
two protons at rather high field (8 7.02, d) and
three protons as unresolved multiplets (8 7.27-
7.37). This significant difference in the.IH NMR of.
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two isomeric compounds 10 and !1 for aromatic
protons is presumably due to hindered rotation of
benzyl group in 10 due to flanking methyl group at
N-7 position, such hindered rotation has earlier
been implicated" for explaining the complex
pattern of aromatic protons in the IH NMR of
isomeric 9-benzyltheophylline 12.
Xanthines are also wel1 known for their
biological properties, for example caffeine 3 and
theophyl1ine are wel1 known for their antial1ergic
activities'". They are also the prototypes of
adenosine receptor antagonists'F' ' and show
phosphodiesterase' activities 13,14. The unusual
chemical shifts of aromatic protons in the 1H NMR
of compound 10 as compared to that of isomeric
compound 11, our continued interest in antial1ergic
activities of pYIJlZolo[3,4-d]pyrimidines coupled
with various biological activities shown by








isomeric monobenzyl dimethyl-4,6-dioxo-4,5,6, 7-
tetrahydro pyrazolo[3,4-d]pyrimidines (13, 19,
25a, 25b and 25c).
The known compound 9b7 required for the
synthesis of desired product 13 was synthesized
from the compound 5b as shown in Scheme I.
Methylation of 5b gave major product 6b having a
N-Me singlet at 0 3.57 in its IHNMR spectrum
alongwith minor product, 7b having a singlet at
04.13 due to OMe protons. Oxidation of 6b
fol1owed by treatment with aqueous alkali gave
required compound 9b in good yield. Benzylation
of 9b gave two isomeric products 13 and 14
(Scheme II) having a two proton singlet for
benzylic protons at 0 5.47 (major product) and 0
5.51 (minor product) in their IHNMR spectra.
This little difference in the chemical shifts of
benzylic protons of compounds 13 and 14 was not
enough for an unambiguous assignment. Definitive
assignment of structure of major product as 13 was
made on the basis of its \3C NMR which showed
presence of a benzylic carbon at 0 47.1 due to its
N~attachment. Normal1y a benzylic carbon attached
to an O-atom appears at much lower field (~ 0 68).
Due to paucity of compound 14 its \3C NMR
spectrum could not be recorded. However,
compound 16, a reasonably close model for
compound 14, showed benzylic carbon attached to
O-atom at 0 68.5, thus providing indirect evidence
for the structural assignment of compounds 13 and
14.
The compound 19 was synthesized using com-
pound 5b8 and the sequence fol1owed for such
conversion is shown in Scheme III. Benzylation of
5b gave a mixture of two isomeric products 15 and
16 which were separated by column
chromatography. The IH NMR spectrum of the
major compound showing benzylic protons at
higher field (0 5.38) was assigned structure 15 and
the minor compound showing corresponding
protons at relatively lower field (05.59) was
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assigned structure 16. This assignment was further
confirmed by the presence of benzylic carbons at 8
46.4 and 68.5 in the 13CNMR spectra of
compounds 15 and 16 respectively. Oxidation of
15 gave sulfone 17 which on alkali treatment gave
compound 18 in good yield. Methylation of 18
gave desired product 19 as a major product
alongwith small amount of isomeric O-methylated
product 20. Structures of the compounds 19 and 20
were established by IHNMR, l3C NMR spectro-
scopy and elemental analysis.
The synthesis of fourth desired product 25a (25,
Rl = Bzl; R2 = R3 = Me) has been described in
literature" starting from compound 24a (24, Rl =
Bzl, R2 = Me) which in turn was prepared by
cyclization of a suitable monocyclic precursor. As
1H NMR data of the compound 25a was not
reported we decided to make this compound by
different procedure starting with compound 21a
(Scheme IV). Methylation of the known compound
21a8 gave a single product 22a (22, Rl = Bzl, R2 =
Me) and none of isomeric O-methyl product was
obtained. Oxidation of 22a gave sulfone 23a which
Scheme IV
on treatment with aqueous alkali gave known
compound 24a (24, R1 = Bzl, R2 = Me).
Methylation of 24a gave the desired product 25a as
only product.
The unknown compound 25b (25, R 1= R2 = Me
; R2 = Bzl) was synthesized using similar sequence
from starting material 21b8 (Scheme IV).
Benzylation of lIb (21, R' = Me) gave compound
22b as only isolable product. Oxidation of 22b (22,
R' = Me, R2 = Bz!) gave sulfone 23b which on
treatment with aqueous alkali gave the product 24b
(24, R' = Me, R2 = Bzl). Finally methylation of
24b gave desired product 25b as a single product
in good yield. Synthesis of the last desired isomer
25c (25, R' = R2 = Me, R3 = Bzl) was achieved
from 21b8 as described in Scheme IV. Methylation
of the compound 21b gave 22c (22, R' = R2 = Me)
as only isolable product. This compound 22c has
been synthesized earlier by a different method,
however, no 'H NMR data was reported'.
Oxidation of the compound 22c gave sulfone 23c
which on aqueous alkali treatment gave the product
24c (24, R' = R2 = Me) in good yield. Benzylation
of 24c gave desired product 25c as only product.
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Possibly due to steric reasons small amount of
O-methylatedlbenzylated products (11, 14 and 20)
were obtained during the preparation of three
desired products (10, 13 and 19) in N-I series but
no such products were obtained during the
synthesis of other three desired isomers (25a, 25b
and 25c) in N-2 series. It is interesting to point out
that in the IH NMR of compounds 19, 25a, 25b
and 25c having relatively unhindered benzylic
groups the two o-protons of phenyl group appear at
87.48, 7.35-7.42, 7.48 and 7.50 respectively.
However, in the IH NMR spectra of compounds 10
and 13 corresponding protons appear at relatively
high field (8 7.02 and 7.14 respectively) due to
steric hinderance by flanking methyl groups.
Extensive use of IH NMR and/or \3CNMR data of
many compounds reported here will be made for
unambiguous assignment of pyrazolo[3,4-
dJpyrimidine analogs of phidolopin and in
determining the conformation (stacked/unstacked)
of some new bis-compounds derived from
intramolecularly stacked 1,3-bis(4,6-dimethylthio-
IH-pyrazolo[3,4-dJpyrimidin-1-yl)propane3,4. Such
studies are in progress and results will be reported
in due course.
Experimental Section
Melting points are uncorrected and were taken
on a Buchi 530 melting point apparatus. Mass
spectra were recorded on a Jeol-JMS D300
spectrometer at an ionization energy of 70 eV. IH
NMR and \3C NMR spectra were recorded on
Bruker WM400 instrument at 400 MHz and 100
MHz respectively. Some IH NMR spectra were
also recorded on a Perkin-Elmer R-32 (90 MHz)
and Varian EM 360L (60 MHz) spectrometer. TLC
plates were prepared with silica gel G and spots
were visualized with h-vapours. Column
chromatography was done on silica gel and purity
of pure compounds were checked in more than one
solvent system.
Methylation/benzylation of cyclic amides:
General procedure. Excess methyl iodidelbenzyl
iodide (:::6 mmole) was added dropwise to a stirred
mixture of compound 5 (5 mrnole), dry DMF (75
mL) and anhyd. K2C03 (excess) and the reaction
mixture was allowed to stir overnight (- 16 hrs).
All DMF was removed at reduced pressure on a
hot water bath and residue was taken up in a
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mixture of water and chloroform. Normal
extraction gave organic layer which was dried
(Na2So.~) and removal of solvent gave crude
product which was purified by column
chromatography followed by crystallization.
Compounds 6, 7, 10, 11, 13, 16, 19,20,22 and 25
were prepared in this way and physical and
spectral data for these are listed in Table I and II.
General procedure for oxidation. To a
solution of 6 (I mmole) in glacial acetic acid (5
mL) and water (5 mL) at ODCwas added solid
KMn04 (2 mmole) in portions and the mixture was
stirred for 1 hr at room temperature. The excess of
KMn04 was decomposed by careful addition of
H202 (30% aq. solution). The colorless solution
was extracted with chloroform, washed with water,
aq. NaHC03 solution and finally with water. The
chloroform layer was dried (Na2S04). Removal of
solvent gave a residue which was crystallized to
give pure product. Physical data and spectroscopic
data of the sulfones (8, 17 and 23) thus prepared
are listed in Table I. .
General procedure for alkaline hydrolysis of
sulfone. A mixture of8 (2 mmole), INNaOH (100
mL), methanol (30 mL) and enough THF (if
required for making homogeneous) was refluxed
for 2-4 hr. The resulting mixture was concentrated
at reduced pressure to remove MeOH -and THF.
The reaction mixture was .cooled and neutralized
with acetic acid. The white solid thus obtained was
collected by filtration washed with water and
dried. Compounds' 9, 18 and 24 were prepared in
this manner and their physical and spectroscopic
data is reported in Table II.
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Table I-Physical data of 1I2,4,5-trisubstituted 1H12H-pyrazolo[3,4-d]pyrimidines (7 and 16) and 1I2,5-disubstituted-











IH NMR (CDCI)) and/or I3C NMR (CDCI)) 0, ppm
(J values in Hz)
6b 90 155 CgHION40S
(EtOAc)
286 2.65 (s, 3H, SCH)), 3.57 (5, 3H, NCH)), 5.47 (5, 2H,
(M+,100) NCH2), 7.33 (brs, 5H, Ar), 8.02 (5, IH, H-3); 15.2,29.4,
50.8, 102.1, 127.7, 127.8, 128.4, 135.0 (C-3), 136.1,
150.3,157.3,157.4,161.8.
210 2.65 (5, 3H, SCH)), 3.57 (5, 3H, NCH)), 3.94 (5, 3H,
(M+,78) NCH)), 7.99 (5, lH, H-3); 15.2, 29.5, 33.6, 102.0, 134.7
(C-3), 150.5, 157.5, 161.6.
286 2.64 (5, 3H, SCH)), 4.12 (s, 3H, OCH)), 5.47 (s, 2H,
(M+, 100). NCH2), 7.25-7.35 (m, 5H, Ar), 7.93 (s, IH, H-3).
210 2.66 (5, 3H, SCH)), 4.03 (s, 3H, NCH)), 4.13 (s, 3H,
(M+,40) OCH)), 7.9 (s, 1H, H-3).
318 3.40 (s, 3H, S02CH)), 3.82 (s, 3H, NCH)), 5.43 (5, 2H,
(M+, 39) NCH2), 7.3 (s, SH, Ar), 8.05 (s, lH, H-3).
242 3.57 (s, 3H, S02Me), 3.92 (s, 3H, NCH)), 4.02 (s, 3H,
(M+,87) NCH)), 8.14 (5, lH, H-3).
270 3.43 (s, 3H, NCH)), 4.09 (5, 3H, OCH)), 5.41 (s, 2H,
(M+, 100) NCH2), 7.25-7.35 (m, 5H, Ar), 8.0 (s, IH, H-3).
270 3.47 (s, 3H, NCH)), 3.91 (s, 3H, NCH)), 5.51 (5, 2H,
(M+,56) NCH2), 7.4-7.5 (rn, 5H, Ar), 7.96 (5, IH, H-3).
286 2.61 (5, 3H, SCH)), 3.96 (5, 3H, NCH)), 5.38 (5, 2H,
(M+,IOO) NCH2), 7.24-7.34, (m, 5H, Ar), 8.03 (5, IH, H-3); 15.4,
33.6, 46.4 127.2 (2C), 127.5, 128.4 (2C), 134.9 (C-3),
135.5,150.5,157.7,161.7.
286 2.65 (s, 3H, SCH)), 4.02 (5, 3H, NCH)), 5.59 (5, 2H,
(M+,45) NCH2), 7.34-7.43 (m, 3H, Ar), 7.49 (d, IH, J=7 Hz, Ar),
7.92 (5, IH, H-3); 14.2,33.8, 68.5 (OCH2), 99.9, 128.3,
128.5, 131.2 (C-3), 135.9, 155.6, 162.2, 169.3.
318 3.56 (5, 3H, S02CH)), 4.04 (5, 3H, NCH)), 5.70 (5, 2H,
(M+,24) \ NCH2), 7.2-7.4 (m, 5H, Ar), 8.12 (5, IH, H-3).
270 3.88 (5, 3H, NCH)), 4.05 (5, 3H, OCH)), 5.23 (5, 2H,
(M+, 100) NCH2), 7.2-7.36 (m, 5H, Ar), 8.0 (5, IH, H-3).
286 2.64 (5, 3H, SCH)), 3.54 (s, 3H, NCH)), 5.38 (5, 2H,
(M+,44) NCH2), 7.3-7.4 (m, 5H, Ar), 7.94 (s, I H, H-3); 15.3, 29.4,
57.3, 104.5, 127.8, 128.2, 128.5, 128.9, 134.6, 157.9,
158.6, 160.6.
286 2.65 (s, 3H, SCH)), 3.94 (s, 3H, NCH)), 5.27 (s, 2H,
(M+,66) NCH2), 7.2 (5, 5H, Ar), 7.90 (s, IH, H-3); 15.5, 40.1, 46.3,
104.4, 127.1, 127.4, 128.4, 128.8, 135.9, 158.0, 158.7,
160.4.
210 2.67 (s, 3H, SCH)), H7 (5, 3H, NCH)), 4.05 (5, 3H,
(M+,75) NCH)), 7.97 (5, IH, H-3).
318(M+,35) (DMSO-d6): 3.35 (5, 3H, S02CH)), 3.95 (5, 3H, NCH)),
5.5 (5, 2H, NCH2), 7.5 (brs, 5H, Ar), 8.7 (5, IH, H-3).
3.56 (5, 3H, S02CH)), 4.13 (5, 3H, NCH)), 5.65 (5, 2H,
NCH2), 7.23--7.31 (m, 5H, Ar), 8.08 (5, IH, H-3).
(CDCI) + DMSO-d6): 3.47 (5, 3H, S02CH)), 3.78 (5, 3H,
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Table II-Physical data of 1I2,5-disubstituted (9,18,24) and 1I2,5,7-trisubstituted-4,6-dioxo-4,5,6,7-tetrahydro-
pyrazolo[3,4-djpyrimidines (10,13,19,25)
Product Yield m.p.oC Mol. MS (70 eV) IH NMR (CDCll) and/or l3C NMR (CDCll) B, ppm
(%) (solvent) formula" rnIz (%) (J values in Hz)
9a 90 265 Cl3H12N402 256 (CDCh+DMSO-d6) 3.38 (s, 3H, NCHl), 5.33 (s, 2H,
(MeOH+CHCll) (M\ 61) NCH2), 7.26 (s, 5H, Ar), 7.84 (s, tH, H-3).
9b 86 >295 C7HsN402 180 3.79 (s, 3H, NCHl), 5.17 (s, 2H, NCH2), 7.2-7.3 (m, 3H,
(MeOH+CHCh) (M.,95) Ar), 7.38 (d, 2H,.I=7 Hz, Ar), 7.91 (s, in, H-3).
10 82 142 Cl4Hl4N40Z 270 3.38 (s, 3H, NCHl), 3.57 (s, 3H, NCH3); 5.65 (s, 2H,
(EtOAc-Hex.) (M+, 100) NCH2), 7.02 (d, 2H,.I=7 Hz, Ar), 7.2777.37 (m, 3H, Ar),
8.02 (s, tH, H-3); 28.3, 31.1, 55.15, 125.5 (2C), 128.2,
129.2, 136.3 (C-3), 136.9, 143.5, 151.4, 157.2.
13 81 170 Cl4Hl4N402 270 3.44 (s, 3H, NCH3), 3.84 (s, 3H, NCH3), 5.47 (s, 2H,
(EtOAc-Hex.) (M+, 48) NCHz), 7.14 (d, 2H, .1=7 Hz, Ar), 7.25-7.50 (m, 3H, Ar),
7.92 (s, tH,H~3); 28.4, 38.9, 47.1, 101.8, 125.1, 127.9,
129.3,135.6,136.4 (C-3), 142.9, 151.7, 157.4.
18 96 290 Cl3H12N402 256 3.79 (s, 3H, NCHl), 5.17 (s, 2H, NCH2), 7.23-7.32 (m, 3H,
(MeOH+CHCh) (~, 51) Ar), 7.38 (d, 2H,.I=7 Hz, Ar), 7.9 (s, tH, H-3).
19 81 165 C14H14N402. 270 3.75 (s, 3H, NCHl), 4.13 (s, 3H, NCHl), 5.17 (s, 2H,
(EtOAc-Hex.) (~, 68) NCH2), 7.2-7.3 (rn, 3H, Ar), 7.48 (d, 2H,.I=7 Hz, Ar), 7.9
(s, in, H-3); 31.3,39.2,44.6, 101.6, 127.4, 128.2, 128.6,
136.5 (C-3), 136.9, 143.4, 151,2, 157 ..1.
24a 90 >300 C13H12N4OZ 256 3.36 (s, 3H, NCH3), 5.40 (s, 2H, NCHz), 7.35 (s, 5H, Ar),
(CHCll) (~, 67) 7.98 (s, IH, H-3), 11.45 (brs, nr, NH).
24b 78 275 Cl3H12N402 256 3.94 (s, 3H, NCHl), 5.16 (s, 2H, NCHz), 7.29-7.32 (m, 3H,
(CHCll-Hex.) (M+, 100) Ar), 7.46 (d, 2H, .1=7 Hz, Ar), 7.85 (s, tH, H-3), 8.68 (brs,
IH, NH).
24c 85 >300 C7HsN402 180 (CDCll+DMSO-d6): 3.18 (s, 3H, NCHl), 3.80 (s, 3H,
(MeOH+CHCh) (~, 100) NCHl), 7.95 (s, in, H-3), 11.5 (brs, m, NH).
25a 85 186 C14Hl4N402 270 3.38 (s, 3H, NCHl), 3.54 (s, 3H, NCHl), 5.29 (s, 2H,
(CHCl]"EtOAc) (~, 100) NCHz), 7.25-7.32 (m, 3H, Ar), 7.35-7.42 (m, 2H, Ar), 7.83
(s, tH, H-3); 27.8, 29.9, 56.7, 101.4, 128.1, 128.6, 128.9,
130.0,134.3,150.8,151.8, 158.5.
25b 91 137 Cl4Hl4N402 270 3.50 (s, 3H, NCHl), 3.94 (s, 3H, NCHl), 5.18 (s, 2H,
(EtOAc-Hex.) (~, 100) NCHz), 7.20-7.30 (m, 3H, Ar), 7.48 (d, 2H,.I=7 Hz, Ar),
7.88 (s, ur, H-3); 29.9, 39.7, 44.3, 101.4, 127.3, 128.2,
128.7, 130.9, 137.6, 151.0, 151.7, 158.4.
25c 92 180 Cl4Hl4N402 270 3.39 (s, 3H, NCH3), 3.95 (s, 3H, NCH3), 5.20 (s, 2H,
(CHCll-Hex.) (~, 49) NCH2), 7.25-7.35 (m, 3H, Ar), 7.50 (d, 2H,.I=7 Hz, Ar),
7.87 (s, IH, H':3); 27.9, 39.8, 47.0, 101.5, 127.7, 128.4,
128.6, 130.6, 136.6, 150.5, 151.7, 158.5.
'All the compounds gave satisfactory analyses (C, ±0.4%; H, ±0.3%; N, ±0.35%)
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